Compare NIU & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | IVVD |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.8M | 201.9M |
| IPO Year | 2018 | 2021 |
| Metric | NIU | IVVD |
|---|---|---|
| Price | $2.03 | $0.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.50 | ★ $8.75 |
| AVG Volume (30 Days) | 224.5K | ★ 2.9M |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $25.54 | $61.57 |
| Revenue Next Year | $17.70 | $41.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $1.93 | $0.49 |
| 52 Week High | $5.67 | $3.07 |
| Indicator | NIU | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 62.91 |
| Support Level | N/A | $0.73 |
| Resistance Level | $2.40 | $1.01 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 6.19 | 96.95 |
Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.